Berlin – Shares in Novo Nordisk experienced a significant downturn on Monday, February 23, 2026, following the release of Phase 3 trial data for its investigational weight-loss drug, CagriSema. The data revealed that CagriSema did not demonstrate superiority to Eli Lilly’s tirzepatide, currently marketed as Mounjaro and Zepbound, in terms of weight loss. This setback casts a shadow over Novo Nordisk’s ambitions to maintain its dominance in the rapidly expanding market for obesity treatments and has prompted analysts to substantially revise their revenue forecasts for the drug. The company’s stock plummeted, reaching its lowest level since June 2021.
The REDEFINE 4 trial, a head-to-head comparison, evaluated the efficacy of CagriSema – a fixed-dose combination of cagrilintide and semaglutide – against tirzepatide in 809 participants with obesity and at least one comorbidity. Participants had a mean baseline body weight of 114.2 kg. After 84 weeks, individuals treated with CagriSema 2.4 mg/2.4 mg achieved an average weight loss of 23.0%, compared to 25.5% weight loss observed in those receiving tirzepatide 15 mg. Crucially, the trial failed to meet its primary endpoint of demonstrating non-inferiority to tirzepatide regarding weight reduction. This outcome is particularly significant given the intense competition in the weight-loss pharmaceutical sector.
CagriSema Trial Results Detailed
The REDEFINE 4 trial was designed as an open-label study, meaning both investigators and participants were aware of the treatment assignments. Novo Nordisk acknowledged that this design could introduce bias, potentially influencing the results. According to the company, when applying a treatment-regimen estimand, CagriSema achieved a weight loss of 20.2% compared to 23.6% with tirzepatide. Despite the failure to meet the primary endpoint, Novo Nordisk highlighted that CagriSema demonstrated a safe and tolerable profile, with the most common adverse events being gastrointestinal in nature and generally mild to moderate, diminishing over time – consistent with the effects observed with GLP-1 receptor agonists.
Novo Nordisk’s research director, Martin Holst Lange, noted the potential for bias inherent in the open-label design of the study. This acknowledgement underscores the complexities of interpreting clinical trial data and the importance of considering methodological limitations. The results have prompted a reassessment of CagriSema’s market potential, with analysts significantly lowering their sales projections.
Market Reaction and Analyst Downgrades
The market reacted swiftly and negatively to the trial results. As of February 23, 2026, Novo Nordisk’s stock was trading at approximately €32.78, reaching a 52-week low. Over the past seven days, the stock has experienced a decline of over 21.26%. This substantial drop reflects investor concerns about the drug’s competitive position and its ability to generate substantial revenue.
Financial analysts have responded by revising their forecasts. Barclays, according to Reuters, has drastically reduced its peak sales estimate for CagriSema from $12 billion to $2 billion. Morningstar also lowered its fair value assessment for Novo Nordisk, from 372 Danish Krone (DKK) to 343 DKK, following a previous reduction to 423 DKK in early February. The firm also decreased its CagriSema revenue forecast for 2035 from 85 billion DKK to 50 billion DKK. These downgrades signal a diminished expectation for CagriSema’s commercial success.
Pipeline Developments and Regulatory Pathway
Despite the setback with CagriSema, Novo Nordisk continues to advance other promising candidates in its pipeline. Notably, the company reported positive results from a Phase 2 study in China evaluating UBT251, a triple-agonist targeting GLP-1, GIP, and glucagon receptors. The study demonstrated a statistically significant average weight loss of up to 19.7% after 24 weeks. This suggests potential for future therapies addressing obesity through a novel mechanism of action.
Novo Nordisk submitted CagriSema for FDA approval in December 2025, and a decision is anticipated by the complete of 2026. Additional studies are underway, including REDEFINE 11, with data expected in the first half of 2027, and a high-dose study planned for the second half of 2026. These ongoing investigations aim to further characterize CagriSema’s efficacy and safety profile and potentially identify optimal dosing strategies. The company remains committed to developing innovative treatments for obesity, despite the recent challenges.
The Competitive Landscape
The disappointing results for CagriSema highlight the intensifying competition in the weight-loss drug market. Eli Lilly’s tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, has rapidly gained market share, surpassing Novo Nordisk’s semaglutide (Ozempic and Wegovy) in U.S. Prescriptions. Lilly recently launched a new formulation of Zepbound offering a month’s supply in a single pen, further enhancing its convenience and appeal to patients. This competitive pressure underscores the require for Novo Nordisk to differentiate its offerings and demonstrate clear clinical advantages.
The failure of CagriSema to demonstrate non-inferiority to tirzepatide raises questions about its positioning in the market. Analysts suggest that Novo Nordisk may need to rely heavily on pricing to compete effectively, potentially impacting profitability. The company’s ability to leverage its existing infrastructure and brand recognition will also be crucial in navigating this challenging landscape.
The development of CagriSema represents a significant investment for Novo Nordisk, combining the actions of both cagrilintide and semaglutide. Semaglutide, already a blockbuster drug in its own right, works by mimicking the effects of the GLP-1 hormone, which regulates appetite and blood sugar levels. Cagrilintide, is an amylin analogue, another hormone involved in appetite control and glucose metabolism. The combination was intended to provide a synergistic effect, leading to greater weight loss than either drug alone. While the 23% weight loss observed with CagriSema is substantial, it falls short of the 25.5% achieved with tirzepatide in the REDEFINE 4 trial.
Looking ahead, the focus will be on the FDA’s review of CagriSema and the results of ongoing clinical trials. The data from REDEFINE 11 and the high-dose study will be critical in determining the drug’s ultimate fate. Novo Nordisk’s success in the weight-loss market will depend on its ability to innovate, adapt to the evolving competitive landscape, and deliver effective and safe treatments for patients struggling with obesity.
Key Takeaways:
- CagriSema failed to demonstrate non-inferiority to tirzepatide in a Phase 3 trial, leading to a significant drop in Novo Nordisk’s stock price.
- Analysts have substantially lowered their revenue forecasts for CagriSema.
- Novo Nordisk is continuing to develop other promising obesity treatments, including the triple-agonist UBT251.
- The competitive landscape in the weight-loss drug market is intensifying, with Eli Lilly’s tirzepatide gaining significant traction.
- A decision on CagriSema’s FDA approval is expected by the end of 2026.
The next key event to watch is the FDA’s decision regarding the approval of CagriSema, anticipated by the end of 2026. We will continue to monitor developments in this rapidly evolving field and provide updates as they become available. What are your thoughts on the future of obesity treatments? Share your comments below.